Why Is Basaglar So Hard to Find? [Explained for 2026]

If you've walked up to a pharmacy counter recently and been told your Basaglar KwikPen is out of stock, you're not alone. While Basaglar itself is not in a formal FDA shortage, millions of people with diabetes are navigating a disrupted insulin glargine market in 2026 — and that disruption is being felt at the pharmacy level.

Here's a plain-English breakdown of what's happening, why you might have trouble finding Basaglar, and what you can do right now.

What Is Basaglar and Who Uses It?

Basaglar (insulin glargine injection) is a long-acting insulin made by Eli Lilly and Company. It was FDA-approved on December 16, 2015, and is used to control blood sugar in adults and children (ages 6 and older) with type 1 diabetes, and in adults with type 2 diabetes. It's injected once daily at the same time each day using the Basaglar KwikPen, a prefilled disposable insulin pen delivering 100 units per mL.

Basaglar has an identical amino acid sequence to Lantus (insulin glargine by Sanofi), the widely used basal insulin. However, Basaglar was approved through an abbreviated 505(b)(2) pathway and is classified as a "follow-on" insulin — not a biosimilar. This distinction matters: pharmacists cannot automatically substitute Basaglar for Lantus or vice versa. Your prescriber must write a prescription specifically for Basaglar.

Is Basaglar Actually in Shortage in 2026?

No — Basaglar KwikPens are not listed on the FDA drug shortage database as of 2026. According to the American Society of Health-System Pharmacists (ASHP), Eli Lilly has Basaglar and Rezvoglar KwikPens available as of early 2026. Nationally, supply from Lilly is intact.

However, one important change is underway: Eli Lilly is discontinuing the Basaglar Tempo Pen by the end of 2026 (available through July 27, 2026 per ASHP). If you use a Tempo Pen, speak to your provider now about transitioning to the KwikPen or another insulin option.

Why Are Some Pharmacies Out of Stock If There's No Shortage?

Even when a drug isn't in a formal national shortage, individual pharmacies can run out. Several factors are creating pockets of unavailability for Basaglar and the broader insulin glargine category:

• The Semglee discontinuation: Biocon discontinued Semglee (insulin glargine-yfgn) on December 31, 2025. Semglee was the most widely used interchangeable biosimilar for Lantus, and millions of patients were on it. Those patients are now being prescribed Lantus, Basaglar, Rezvoglar, or generic insulin glargine — suddenly straining supply chains for all glargine products.
• Formulary changes in real time: Insurance plans that previously covered Semglee are scrambling to update their formularies. Some plans have switched patients to Basaglar, increasing demand at certain pharmacy networks faster than stock can be replenished.
• Distribution lag: Even with adequate national supply, local distribution networks take time to restock. A pharmacy that didn't historically carry large quantities of Basaglar may need to order more — causing a temporary gap.
• Pen format confusion: The Tempo Pen discontinuation means some pharmacies have cleared Tempo Pen inventory without fully stocking up on KwikPens, creating a temporary availability gap.

Does the Basaglar Tempo Pen Discontinuation Affect Me?

If your prescription is written specifically for the Basaglar Tempo Pen, you may find it harder to fill as 2026 progresses. Eli Lilly has confirmed Tempo Pens will be available through July 27, 2026. After that date, you can continue using Tempo Pens until their expiration date — but the TempoSmart app and Tempo Platform will stop recording diabetes-related data on July 28, 2026, and will be fully discontinued on December 31, 2026.

The practical advice: if you're using Tempo Pens, ask your provider to switch your prescription to Basaglar KwikPen now. The dose is the same (1:1 unit conversion), and you'll avoid scrambling to find an increasingly scarce product later in the year.

What Should You Do If Your Pharmacy Doesn't Have Basaglar?

Being turned away at the pharmacy when you need insulin is not just an inconvenience — it's a medical issue. Here are the steps to take:

1. Call other pharmacies. Don't assume all pharmacies in your area are out. Independent pharmacies, specialty pharmacies, and large chains often have different inventory levels.
2. Use medfinder. medfinder calls pharmacies near you to check which ones can fill your Basaglar prescription. You provide your medication, dosage, and zip code — medfinder does the calling and texts you results. No need to call 10 pharmacies yourself.
3. Ask your provider about alternatives. If Basaglar truly isn't available near you, your provider may be able to switch you to Lantus, Rezvoglar, Toujeo, or Tresiba depending on your insurance and medical needs. Note: switching insulins requires a new prescription and possibly dose adjustment.
4. Check mail-order pharmacy options. Many insurance plans offer 90-day supplies through mail-order pharmacies, which often have more reliable inventory for maintenance medications like basal insulin.
5. Refill early. Most insurance plans allow you to refill your insulin 7–10 days before you run out. Use this window to identify a pharmacy with stock and avoid being caught without insulin.

Will Basaglar Availability Improve in 2026?

The outlook is cautiously optimistic. Eli Lilly continues to manufacture Basaglar KwikPens, and the overall insulin glargine supply is supported by multiple manufacturers including Sanofi (Lantus, Toujeo), Eli Lilly (Basaglar, Rezvoglar), and Winthrop (generic insulin glargine vials and pens). As insurance formularies stabilize following the Semglee exit, the scramble for alternative products should ease.

That said, if your specific pharmacy doesn't stock Basaglar in large quantities, localized stockouts will continue to happen. The best protection is knowing how to quickly locate a pharmacy that has your insulin in stock — which is exactly what medfinder is designed to help with.

Key Takeaways

• Basaglar KwikPens are NOT in an FDA shortage — Eli Lilly confirms availability as of 2026.
• Basaglar Tempo Pens are being discontinued — available only through July 27, 2026.
• Individual pharmacies may be out of stock due to increased demand caused by the Semglee discontinuation in late 2025.
• Calling multiple pharmacies or using medfinder can help you locate Basaglar quickly.
• If Basaglar isn't available, ask your provider about alternatives — see our guide to Basaglar alternatives for a detailed comparison.

Ready to find Basaglar in stock near you? Read our step-by-step guide: How to find Basaglar in stock near you.